- Home
- NTIP vs COEP Comparison
NTIP vs COEP Comparison
Compare NTIP & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | COEP |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 100.4M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | NTIP | COEP |
|---|---|---|
| Price | $1.32 | $14.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.4K | ★ 115.0K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | ★ 7.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $150,000.00 | ★ $500,996.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.16 | $2.31 |
| 52 Week High | $1.90 | $21.41 |
Technical Indicators
Market Signals| Indicator | NTIP | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 47.83 |
| Support Level | $1.32 | $13.61 |
| Resistance Level | $1.42 | $15.53 |
| Average True Range (ATR) | 0.07 | 1.07 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 3.06 | 51.42 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.